A Phase 4 interventional study of Sublingual film containing Igalmi in Bipolar Disorder, Schizophrenia and Agitation,Psychomotor, sponsored by BioXcel Therapeutics Inc. Completed at 2 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-11.
Sponsored by BioXcel Therapeutics Inc · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 837 studies in Bipolar Disorder with a site in United States — 77 open to participants now, 96 under way, 8 of them phase 3. Bipolar Disorder · United States.
Among the 837 studies in Bipolar Disorder with a site in United States, this one is the 511th largest by enrollment of the 704 interventional ones that give a count, is one of 26 that started in 2023, is one of 155 in phase 4, and was the 758th registered.
1,685 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.
Browse Bipolar Disorder studies →77 of the 837 studies in Bipolar Disorder with a site in United States are open now. Recruiting first, the newest first:
Stanford University · Sites in United States
Ages 18–80
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 22–70
Massachusetts General Hospital · Sites in United States
Ages 18–65
Massachusetts General Hospital · Sites in United States
Ages 18–65
AbbVie · Sites in United States
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
837 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 56 · Phase 2 119 · Phase 3 129 · Phase 4 155
First in 1979; this study’s year is marked. 26 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 29 is below the median of 64 across 1,280 interventional studies indexed under Bipolar Disorder.
Median enrollment 58 across the 704 interventional studies, 107 across the 128 observational. Of the 695 that completed or were terminated, 305 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
148 of 837 have an industry lead sponsor. The 10 most frequent:
BioXcel Therapeutics Inc is the lead sponsor of 15 studies on the registry; 1 is open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 9 (75%) have results posted.
BioXcel Therapeutics Inc has 5 studies filed under Bipolar Disorder — fewer than ten, so there is no comparison to draw.
37 of the studies in Bipolar Disorder with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07140913Phase 3Bristol-Myers SquibbA Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine | 2027-06-28 |
| NCT05457127University of California, San DiegoObstructive Sleep Apnea Treatment in Serious Mental Illness | 2026-11 |
| NCT03573349Mayo ClinicKetamine Associated ACC GABA and Glutamate Change and Depression Remission: | 2026-12 |
| NCT03349528Sheppard Pratt Health SystemProbiotics to Prevent Relapse After Hospitalization for Bipolar Depression | 2026-12 |
| NCT06226025Leslie SwansonCorrecting Circadian Rhythms to Breakthrough in Bipolar Disorder | 2026-12 |
Add all 37 to your calendar (.ics) → With an account.
Among the 837 studies in Bipolar Disorder with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an in-clinic, single arm, open-label study assessing tachyphylaxis, tolerance, and withdrawal following repeated doses of Igalmi in adult males and females with agitation associated with schizophrenia or bipolar disorder.
This is an in-clinic, single arm, open-label study assessing tachyphylaxis, tolerance, and withdrawal following repeated doses of Igalmi in adult males and females (18 to 65 years old, inclusive) with agitation associated with schizophrenia or bipolar disorder. Subjects will be screened for eligibility within 15 days of first dose and no study procedures will occur unless subjects provide written informed consent. Subjects will receive single doses of 180 μg of Igalmi as needed for the treatment of agitation over a period of 7 days followed by a 3- day follow-up period during which time no Igalmi will be administered in an effort to characterize any potential withdrawal. Subjects will sublingually self-administer Igalmi for an agitation episode that reaches a pre-dose PEC total score of 14 or greater, as determined by a trained rater. Safety assessments will be conducted before and after each dose. If the subject's agitation is recurrent or persistent, repeat doses of 90 µg may be administered (no more than 2 repeat doses within a 24-hour period) in the absence of any safety concerns or adverse events.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An initial dose of 180 µg of Igalmi as needed for the treatment of agitation over a period of 7 days. In the event of persistent or recurrent agitation, investigators may choose to repeat dose at 90 μg after the 2-hour time point in the absence of dose-limiting adverse events or safety concerns. A maximum of 2 repeat doses will be allowed in a 24-hour period.
Drug: Sublingual film containing Igalmi
Sublingual film containing 180 µg of Igalmi (dexmedetomidine)
Also known as: Dexmedetomidine, BXCL501
Change From Baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score
The Positive and Negative Syndrome Scale-Excited Component (PEC) includes 5 items-poor impulse control, tension, hostility, uncooperativeness, and excitement-each of which is rated from 1 (minimum) to 7 (maximum); the sum of these 5 items, the PEC total score, ranges from 5 (absence of agitation) to 35 (extremely severe).
Time frame: Baseline and 2 hours post-dose for all doses administered over 7 days.
Clinical Global Impression - Improvement (CGI-I)
The Clinical Global Impression - Improvement (CGI-I) for agitation in response to treatment measures the current level of agitation relative to the level of agitation prior to administration of study intervention. The CGI-I scores range from 1 to 7 with a score of 1 indicating very much improved, and a score of 7 indicating very much worse.
Time frame: 2 hours post-dose for all doses administered over 7 days.
Number of Participants With Adverse Events During the Follow-up Period
Evaluation of withdrawal phenomenon based on the occurrence of adverse events such as tachycardia, systolic hypertension, nausea, or vomiting and the emergence of any new adverse events on ≥2 consecutive days of the 3-day off-treatment follow-up period.
Time frame: Day 8 through Day 10
The study was conducted in the United States from 02Oct2023 to 29Apr2024.
| Milestone | Active Treatment - 180 mcg of Igalmi (Dexmedetomidine) |
|---|---|
| Started | 29 |
| Completed | 28 |
| Not completed | 1 |
| Withdrew: Withdrawal by subject | 1 |
The Positive and Negative Syndrome Scale-Excited Component (PEC) includes 5 items-poor impulse control, tension, hostility, uncooperativeness, and excitement-each of which is rated from 1 (minimum) to 7 (maximum); the sum of these 5 items, the PEC total score, ranges from 5 (absence of agitation) to 35 (extremely severe).
| score on a scale | Active Treatment - 180 mcg of Igalmi (Dexmedetomidine) |
|---|---|
| Dose 1 | -10.4 ± 2.94 |
| Dose 2 | -10.0 ± 3.54 |
| Dose 3 | -10.1 ± 3.60 |
| Dose 4 | -9.8 ± 2.55 |
| Dose 5 | -11.5 ± 4.51 |
| Dose 6 | -8.7 ± 3.79 |
| Dose 7 | -11.0 ± NA |
The Clinical Global Impression - Improvement (CGI-I) for agitation in response to treatment measures the current level of agitation relative to the level of agitation prior to administration of study intervention. The CGI-I scores range from 1 to 7 with a score of 1 indicating very much improved, and a score of 7 indicating very much worse.
| score on a scale | Active Treatment - 180 mcg of Igalmi (Dexmedetomidine) |
|---|---|
| Dose 1 | 1.2 ± 0.50 |
| Dose 2 | 1.2 ± 0.39 |
| Dose 3 | 1.3 ± 0.47 |
| Dose 4 | 1.0 ± 0.00 |
| Dose 5 | 1.2 ± 0.41 |
| Dose 6 | 1.3 ± 0.58 |
| Dose 7 | 2.0 ± NA |
Evaluation of withdrawal phenomenon based on the occurrence of adverse events such as tachycardia, systolic hypertension, nausea, or vomiting and the emergence of any new adverse events on ≥2 consecutive days of the 3-day off-treatment follow-up period.
| Participants | Active Treatment - 180 mcg of Igalmi (Dexmedetomidine) |
|---|---|
| Number of Participants With Adverse Events During the Follow-up Period | 0 |
Collected over 10 days. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Active Treatment - 180 mcg of Igalmi (Dexmedetomidine) | 0/28 (0%) | 0/28 (0%) | 14/28 (50%) |
| Event | Active Treatment - 180 mcg of Igalmi (Dexmedetomidine) |
|---|---|
| HeadacheNervous system disorders | 3/28 |
| SomnolenceNervous system disorders | 3/28 |
| Dry mouthGastrointestinal disorders | 3/28 |
| HypotensionVascular disorders | 3/28 |
| DizzinessNervous system disorders | 1/28 |
| SyncopeNervous system disorders | 1/28 |
| DyspepsiaGastrointestinal disorders | 1/28 |
| Gastroesophageal reflux diseaseGastrointestinal disorders | 1/28 |
| Hypoesthesia oralGastrointestinal disorders | 1/28 |
| Orthostatic hypotensionVascular disorders | 1/28 |
| Age, Continuous(years) | Active Treatment - 180 mcg of Igalmi (Dexmedetomidine) |
|---|---|
| Mean | 45.4 ± 8.85 |
| Sex: Female, Male(Participants) | Active Treatment - 180 mcg of Igalmi (Dexmedetomidine) |
|---|---|
| Female | 10 |
| Male | 19 |
| Ethnicity (NIH/OMB)(Participants) | Active Treatment - 180 mcg of Igalmi (Dexmedetomidine) |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 28 |
| Unknown or Not Reported | 1 |
| Race (NIH/OMB)(Participants) | Active Treatment - 180 mcg of Igalmi (Dexmedetomidine) |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 13 |
| White | 15 |
| More than one race | 1 |
| Unknown or Not Reported | 0 |
| Diagnosis(Participants) | Active Treatment - 180 mcg of Igalmi (Dexmedetomidine) |
|---|---|
| Bipolar 1 or 2 | 17 |
| Schizophrenia | 10 |
| Schizoaffective disorder | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2023 to primary completion in Apr 2024, 6 months.
Results were first posted in Jan 2026, 1 year 8 months after primary completion.
Of 44 phase 4 interventional studies under Bipolar Disorder, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 60. This study's 6 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexmedetomidine
BioXcel Therapeutics Inc